The Indonesia Eximbank (LPEI) has provided a working capital export credit facility worth IDR 300 billion to PT Bio Farma (Persero) through the Pharmaceutical and Medical Devices Export Special Assignment (PKE) program. This credit facility underscores LPEI’s commitment to enhancing the global competitiveness of Indonesia's pharmaceutical industry. The partnership between LPEI and Bio Farma strengthens the development of Indonesia's pharmaceutical sector and boosts the international competitiveness of Indonesian pharmaceutical products. According to the Ministry of Industry, the export value of Indonesia’s pharmaceutical and natural medicine industry reached USD 639.42 million (approximately IDR 9.9 trillion) from January to September 2024.
The credit agreement was signed by LPEI’s Business Division III Head, Nurrohmanudin, and Bio Farma’s Finance and Risk Management Director, IGN Suharta Wijaya, with the presence of LPEI Business Director Anton Herdianto, Acting Business Development Director Maqin U. Norhadi, and Bio Farma’s CEO, Shadiq Akasya. Anton Herdianto explained that the agreement is a tangible step towards enhancing Indonesia's pharmaceutical industry independence through the PKE program. Bio Farma plays a vital role in supporting vaccination programs and expanding international market reach, which reflects the global trust in its vaccine products. Bio Farma, as the largest vaccine producer in Indonesia, is committed to producing high-quality vaccines and contributing to national health resilience. With a production capacity of 3.1 billion doses per year and 52% of its total production being exported, Bio Farma continues to strengthen its global position, currently ranking 9th in the WHO Global Vaccine Market Report 2023.
